Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerSuzanne L. Topalian, Mario Sznol, Alan J. Korman et al.|New England Journal of Medicine|2012Cited by 12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerJulie R. Brahmer, Jon M. Wigginton, Scott S. Tykodi et al.|New England Journal of Medicine|2012Cited by 8k
Nivolumab plus Ipilimumab in Advanced MelanomaJedd D. Wolchok, Mario Sznol, Harriet M. Kluger et al.|New England Journal of Medicine|2013Cited by 4.2k
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque ToxicologyMark Selby, Alan J. Korman|PLoS ONE|2016Cited by 228
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer targetZachary T. Freeman, Charles G. Drake, Thomas R. Nirschl et al.|Journal of Clinical Investigation|2020Cited by 133